Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 01 Mar 2022
Lexicon voluntarily withdraws sotagliflozin new drug application and plans prompt resubmission targeted early Q2 2022
28 February 2022 - Resubmission to Correct Recently-Identified Technical Issue. ...
Posted by Michael Wonder on 01 Mar 2022
New PBS listings from 1 March 2022
1 March 2022 - Australians will have access to four new medicines through the Pharmaceutical Benefits Scheme from March 1 to ...
Posted by Michael Wonder on 01 Mar 2022
Kiwis call on Government to increase PHARMAC funding to help fund Spinraza treatment
1 March 2022 - A group of Kiwis are calling on the Government to increase PHARMAC funding to provide better ...
Posted by Michael Wonder on 01 Mar 2022
Glucophage is the first oral diabetes treatment approved in Europe for use during pregnancy
28 February 2022 - The approval was granted on the basis of Merck’s own safety cohort study CLUE and a large ...
Posted by Michael Wonder on 01 Mar 2022
AbbVie provides update regarding Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe Crohn's disease in the U.S.
28 February 2022 - AbbVie today announced that the U.S. FDA has extended its review period for Skyrizi (risankizumab-rzaa) for ...
Posted by Michael Wonder on 28 Feb 2022
Flu vaccine price increase
1 March 2022 - PHARMAC has confirmed that the purchase price of the annual influenza vaccine will increase by $2 ...
Posted by Michael Wonder on 28 Feb 2022
AbbVie seeks new indication for Imbruvica (ibrutinib) in paediatric patients with chronic graft versus host disease
28 February 2022 - The sNDA and NDA submissions were primarily based on results of three years of data from ...
Posted by Michael Wonder on 28 Feb 2022
Amryt receives complete response letter from the FDA for Oleogel-S10 NDA
28 February 2022 - Amryt receives complete response letter from the FDA for Oleogel-S10 NDA. ...
Posted by Michael Wonder on 28 Feb 2022
Astellas and Seagen announce CHMP confirms positive opinion for Padcev (enfortumab vedotin) in locally advanced or metastatic urothelial cancer
28 February 2022 - Astellas Pharma and Seagen today announced that the CHMP of the EMA has confirmed its previously ...
Posted by Michael Wonder on 28 Feb 2022
New Zealand Pharmaceutical Schedule - 1 March 2022
1 March 2022 - The March 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 28 Feb 2022
Lagevrio (molnupiravir) PBS listing
1 March 2022 - Commencing 1 March 2022, Lagevrio (molnupiravir) will be listed on the PBS Section 85 program as an ...
Posted by Michael Wonder on 28 Feb 2022
Bristol Myers Squibb receives positive CHMP opinion for Opdivo (nivolumab) plus chemotherapy for first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%
25 February 2022 - Recommendation based on positive results from the Phase 3 CheckMate -648 trial, in which the combination demonstrated ...
Posted by Michael Wonder on 28 Feb 2022
Schedule of Pharmaceutical Benefits - 1 March 2022
1 March 2022 - The March 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 28 Feb 2022
Bristol Myers Squibb receives positive CHMP opinion recommending approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma
25 February 2022 - Recommendation based on results from the Phase 3 CheckMate -648 trial, in which the immunotherapy combination demonstrated ...
Posted by Michael Wonder on 28 Feb 2022
JW Therapeutics announces NMPA acceptance of the supplemental new drug application for Carteyva in patients with relapsed or refractory follicular lymphoma
27 February 2022 - JW Therapeutics announced that the National Medical Products Administration of China accepted the supplemental new drug ...